Navigation Links
New Ovarian Cancer Drug Trial Under Way
Date:9/7/2007

Phenoxodiol could help women resistant to other medicines

FRIDAY, Sept. 7 (HealthDay News) -- Ovarian cancer patients whose cancer has become resistant to traditional chemotherapy can now log-on to a new Web site to learn about a trial of a new drug, phenoxodiol.

In previous studies, phenoxodiol has shown some success in helping traditional chemotherapies continue to fight cancer cells.

The Phase III study of phenoxodiol will take place at 30 sites in the United States, 26 sites in Europe and at least four sites in Australia.

The goal of the Web site, www.OVATUREtrial.com, is to inform ovarian cancer patients about the Ovarian Tumor Response (OVATURE) trial, which is actively recruiting patients. Women suffering with ovarian cancer can learn about the study, the medication and locations for them to participate.

The trial is studying the safety and effectiveness of the drug phenoxodiol when combined with weekly doses of the chemotherapy drug carboplatin. Phenoxodiol is believed to help chemotherapy drugs kill chemoresistant cancer cells by removing factors in the cells that block the killing action of chemotherapy. Phenoxodiol has not yet been approved for use by the U.S. Food and Drug Administration.

Women who enter the trial will be assigned to one of two courses of treatment. The first will receive weekly carboplatin and phenoxodiol. Patients in the other course will receive carboplatin and a placebo weekly. Patients and their doctors will not know which course of treatment they have been given.

Receiving carboplatin weekly instead of every two or three weeks has been shown to provide tumor response in some patients with recurrent ovarian cancer. The study will expand understanding of the safety and effectiveness of both phenoxodiol and weekly carboplatin.

Phenoxodiol has been shown to reverse resistance to standard chemotherapies in lab animals. In a prior Phase II clinical trial
'/>"/>

Copyright©2007 ScoutNews,LLC.
All rights reserved

Page: 1 2

Related medicine news :

1. Ovarian cancer in relationship with Hormone therapy
2. Progestin protects against ovarian cancer
3. Inherited gene important in ovarian cancer
4. Blood test may identify ovarian cancer
5. Exercise lowers Risk of Ovarian Cancer
6. Screening device for ovarian cancer
7. Ethnic discrepancy in ovarian cancer
8. Associated scan for detecting ovarian cancer spread
9. Gene Mutation Causes Ovarian Failure
10. Ovarian Cancer Screening Questioned
11. Thawed Ovarian Transplant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... the most popular vaccine brands for children may not ... overlooking some cost factors when choosing vaccines, driving the ... according to a new study by University of Illinois ... be driven by numerous factors," says Sheldon H. Jacobson, ... computer science and of mathematics at the U. of ...
(Date:4/17/2014)... review published in the April issue of Immunity ... Institute for Medical Research, says it,s time to take ... to treating sepsis, which kills millions worldwide every ... when molecules released into the bloodstream to fight an ... is necessary for maintaining good health without inflammation, ...
(Date:4/17/2014)... It,s estimated that as many as 10 million older ... of loneliness and isolation. , However, new research ... retired older Americans for six years found that ... of depression by more than 30 percent. , "That,s ... State University professor of telecommunication, information studies and media ...
(Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit ... issues, published a comprehensive review today examining the current ... virus. The review calls for improved global surveillance strategies ... the recent outbreak of Ebola in West Africa that ... countries of Guinea and Liberia. According to the ...
(Date:4/17/2014)... ribbon representing a disease. A pink ribbon is well known ... think of with lung cancer?, Although white has been identified ... black may be the only one they think fits., A ... smokers between the ages of 51 to 79 years old, ... these patients, the emotional toll it can have and how ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Internet use can help ward off depression among elderly 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Unraveling the 'black ribbon' around lung cancer 2
... McClellan to Keynote Afternoon Session on Legal, Regulatory ... personalized medicine,revolutionize healthcare in the United States?, ... at a national conference,Personalized Medicine: Promises and Challenges, ... Science (AAAS) and the Food and Drug Law,Institute ...
... announced today that the company presented results from a ... (palivizumab) as a preventive measure against respiratory syncytial virus ... leading cause of viral respiratory infection among preterm infants. ... born at 32-to-35 weeks gestational age were reviewed. ...
... becomes the first Medicare ... contractor to receive certification, CAMP ... (COPC Inc.) recently announced that Highmark Medicare Services,has achieved ... will continue to align their current Provider Contact Center,operations ...
... joins The Libby Ross Foundation to ... unveil celebrity-designed yoga bags, NEW YORK, May 5 ... Ross Foundation to help empower women,battling breast cancer through the charity,s ... has joined the,cause to raise funds for this unique program by ...
... 5 HealthMedia(R), the global,leader in scalable ... significant growth -- doubling its first quarter ... 60 percent and revenue,from partnerships with strategic ... One new program contributing to this growth ...
... According to new,research findings published today in ... and enforce strong tobacco control policies,more than 17,000 ... just the next fifteen to twenty years. Kentucky ... United States. Kentucky also has weak,public policies addressing ...
Cached Medicine News:Health News:AAAS, FDLI Sponsor Landmark Meeting on Personalized Medicine June 20, 2008 2Health News:AAAS, FDLI Sponsor Landmark Meeting on Personalized Medicine June 20, 2008 3Health News:Highmark Medicare Services Achieves Certification to COPC-2000(R) CSP Standard 2Health News:Highmark Medicare Services Achieves Certification to COPC-2000(R) CSP Standard 3Health News:Celebrity Mothers and Daughters Including Miley and Trish Cyrus Join Swarovski to Support Breast Cancer Survivors 2Health News:HealthMedia(R) Explosive Growth Continues in First Quarter 2008 2Health News:HealthMedia(R) Explosive Growth Continues in First Quarter 2008 3Health News:Study Suggests Stronger Tobacco Control Policies in States With High Smoking Rates Would be Effective in Reducing Smoking and Saving Thousands of Lives 2Health News:Study Suggests Stronger Tobacco Control Policies in States With High Smoking Rates Would be Effective in Reducing Smoking and Saving Thousands of Lives 3
(Date:1/15/2014)... Fla. , Jan. 15, 2014  In an unprecedented effort to ... TB in ambulances and other transport vehicles, an advanced and portable ... rescue personnel for the first time. In order ... with these deadly pathogens, West Palm Beach ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium ... technology market intelligence, the United States ... (TEO) device markets will expand moderately through 2022, ... segments. In particular, increasing interest in drug-eluting beads ...
(Date:1/15/2014)... NEW YORK , Jan. 15, ... new market research report is available ... Global Markets and Technologies for ... on Routes of Administration ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
... in Combination with Chemotherapy, FREMONT, Calif. ... pharmaceutical company discovering and developing novel,RNA interference ... Research published results on efficacy of siRNA ... lung cancer (NSCLC) in,the edition dated October ...
... Pivotal Data Show Prophylaxis Treatment with Kogenate FS ... in Children with No Pre-Existing,Joint Damage, BERKELEY, ... that the U.S. Food and Drug Administration (FDA) ... to reduce the frequency of bleeding episodes and ...
Cached Medicine Technology:Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 2Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 3Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 4FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 2FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 3FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 4FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 5
The Surgiflex WAVE XP couples the state-of-the-art Surgiflex WAVE Probe with the convenience of a truly portable battery-powered pump....
... GYNECARE TVT is a minimally invasive, ... of stress urinary incontinence. GYNECARE TVT is ... of the urethra, and when needed, TVT ... the correct position. The procedure takes approximately ...
...
...
Medicine Products: